Director George L. Sing of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) filed a Form 4 on November 4, 2026, disclosing option exercises and open-market share sales totaling 21,129 shares on November 2, 2026.
Key Highlights
- Option exercises: George L. Sing exercised two non-qualified stock options on November 2, 2026, acquiring 7,830 shares at $376.69 and 7,439 shares at $380.95.
- Shares sold: Sing disposed of a total of 21,129 shares of Regeneron common stock on November 2, 2026, across nine separate sale tranches.
- Sale price range: The sales were executed at volume-weighted average prices ranging from $960.57 to $970.18 per share, with individual tranche prices spanning $960.03 to $970.19.
- Remaining direct holdings: Following all reported transactions, Sing directly held 25,147 shares of common stock.
- Indirect holdings: The filing also reports 750 shares held by spouse, 400 shares held by spouse/custodian for son, and 1,000 shares held by a trust for son.
- Options extinguished: Both exercised options were reduced to zero shares remaining, with expiration dates of January 3, 2027 and January 2, 2028, respectively.
George Sing's November 2 Option Exercises and Share Sales at Regeneron
According to the Form 4 filed with the SEC on November 4, 2026, George L. Sing, a director of Regeneron Pharmaceuticals, Inc., exercised two non-qualified stock options on November 2, 2026. The first exercise involved 7,830 shares at an exercise price of $376.69, and the second involved 7,439 shares at $380.95. The filing states that each option "vested in three equal annual installments, commencing one year after the date of grant."
On the same date, the filing reports that Sing sold 21,129 shares in nine separate tranches, each reported at a volume-weighted average price. The tranches ranged from 200 shares at a weighted average of $970.18 to 7,073 shares at a weighted average of $965.38. Per the filing's explanatory footnotes, each reported price represents a volume-weighted average, and Sing has committed to providing full detail on per-share prices to the Commission staff, the company, or a security holder upon request.
After all transactions, Sing directly owned 25,147 shares of Regeneron common stock, according to the filing. Additional indirect beneficial ownership is reported as 750 shares held by spouse, 400 shares held by spouse as custodian for son, and 1,000 shares held by a trust for son. The filing was signed by George L. Sing on November 4, 2026, and covers transactions that occurred on November 2, 2026, the date of earliest transaction noted on the form.
What Was Disclosed
The filing disclosed two stock option exercises and nine open-market share sales by Regeneron director George L. Sing on November 2, 2026, resulting in direct beneficial ownership of 25,147 shares following the reported transactions.



Please wait processing your request...